Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review

#1719

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.

Aim(s): To determine the benefits and harms of escalated dose SSAs in treatment of metastatic GEPNETs.

Materials and methods: Eligible trials of dose-escalated SSA (more than 30mg octreotide or 120mg lanreotide every 28 days) were identified from major databases and conference proceedings. Disease control rate (DCR), objective response rate (ORR), biochemical response, symptomatic improvement and toxicity were abstracted. Trials were synthesized qualitatively.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Chan D, Ferone D, Segelov E, Albertelli M, Singh S,

Keywords: Escalated dose, octreotide, lanreotide, SSA,